Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e614 (Published 2 March 2012)
Cite this as: BMJ 2012;344:e614

Related articles

Analysis: No more disease silos for sub-Saharan Africa

Correction: Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study

Analysis: What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia?

Research: Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study

Research: Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study

Research: Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study

Research: Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study

Research: Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis

Research: Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study

Education and debate: Evaluation of current strategies and future priorities for improving health in developing countries

EDUCATION AND DEBATE: Evaluation of current strategies and future priorities for improving health in developing countries

Education and debate: Methods to assess the costs and health effects of interventions for improving health in developing countries

See more

Practice: Ordering and interpreting hepatitis B serology

News: Tamiflu purchase worth £49m will go ahead, government says

Clinical Review: Anticoagulation in atrial fibrillation

News: Cochrane review questions effectiveness of neuraminidase inhibitors

This article has been cited by other articles:

THIS WEEK'S POLL